CTI BioPharma Corp. – NASDAQ:CTIC
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
CTI BioPharma Corp. stock price monthly change
+1.68%
month
CTI BioPharma Corp. stock price quarterly change
+104.73%
quarter
CTI BioPharma Corp. stock price yearly change
+48.29%
year
CTI BioPharma Corp. key metrics
Market Cap | 1.19B |
Enterprise value | 583.32M |
P/E | -5.23 |
EV/Sales | 10.81 |
EV/EBITDA | -7.58 |
Price/Sales | 10.45 |
Price/Book | -32.07 |
PEG ratio | -0.20 |
EPS | -0.64 |
Revenue | 75.76M |
EBITDA | -50.90M |
Income | -77.01M |
Revenue Q/Q | 950.80% |
Revenue Y/Y | 3201.48% |
Profit margin | -172.37% |
Oper. margin | -147.91% |
Gross margin | 93.49% |
EBIT margin | -147.91% |
EBITDA margin | -67.18% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCTI BioPharma Corp. stock price history
CTI BioPharma Corp. stock forecast
CTI BioPharma Corp. financial statements
| Jun 2022 | 12.32M | -22.66M | -183.83% |
|---|---|---|---|
| Sep 2022 | 18.24M | -15.62M | -85.68% |
| Dec 2022 | 21.08M | -16.92M | -80.28% |
| Mar 2023 | 24.11M | -21.79M | -90.38% |
| Jun 2022 | 134534000 | 139.80M | 103.92% |
|---|---|---|---|
| Sep 2022 | 123466000 | 140.30M | 113.64% |
| Dec 2022 | 125925000 | 143.50M | 113.96% |
| Mar 2023 | 112272000 | 137.61M | 122.58% |
| Jun 2022 | -20.24M | -54.78M | 44.22M |
|---|---|---|---|
| Sep 2022 | -15.46M | -19.60M | 1.02M |
| Dec 2022 | -15.51M | 537K | 13.34M |
| Mar 2023 | -31.09M | 15.25M | 9.63M |
CTI BioPharma Corp. alternative data
| Aug 2023 | 127 |
|---|---|
| Sep 2023 | 127 |
| Oct 2023 | 127 |
| Nov 2023 | 127 |
| Dec 2023 | 127 |
| Jan 2024 | 127 |
| Feb 2024 | 127 |
| Mar 2024 | 127 |
| Apr 2024 | 127 |
| May 2024 | 127 |
| Jun 2024 | 127 |
| Jul 2024 | 127 |
CTI BioPharma Corp. other data
86.37%
-3.63%
of CTIC is owned by hedge funds
142
+16
105.01M
+7.35M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2022 | 0 | 132223 |
| Jul 2022 | 0 | 92344 |
| Aug 2022 | 5000 | 8500000 |
| Sep 2022 | 0 | 404833 |
| Oct 2022 | 0 | 909 |
| Nov 2022 | 0 | 333800 |
| Dec 2022 | 0 | 32421 |
| Jan 2023 | 0 | 213821 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | CRAIG ADAM R director, officer.. | Non-Qualified Stock Option (right to buy) | 2,117 | $0.84 | $1,780 | ||
Option | CRAIG ADAM R director, officer.. | Non-Qualified Stock Option (right to buy) | 83,200 | $0.84 | $69,971 | ||
Option | CRAIG ADAM R director, officer.. | common stock | 2,117 | $0.84 | $1,780 | ||
Sale | CRAIG ADAM R director, officer.. | common stock | 2,117 | $6.01 | $12,723 | ||
Option | CRAIG ADAM R director, officer.. | common stock | 83,200 | $0.84 | $69,971 | ||
Option | FONG JAMES K officer: EVP & Chief Commercial.. | Non-Qualified Stock Option (right to buy) | 100,000 | $0.95 | $94,900 | ||
Sale | FONG JAMES K officer: EVP & Chief Commercial.. | common stock | 100,000 | $6 | $600,000 | ||
Option | FONG JAMES K officer: EVP & Chief Commercial.. | common stock | 100,000 | $0.95 | $94,900 | ||
Option | CRAIG ADAM R director, officer.. | Non-Qualified Stock Option (right to buy) | 84,683 | $0.84 | $71,218 | ||
Sale | CRAIG ADAM R director, officer.. | common stock | 84,683 | $6.01 | $509,199 |
| Patent |
|---|
Application Filling date: 2 Sep 2021 Issue date: 4 Aug 2022 |
Application Filling date: 1 Oct 2019 Issue date: 13 Jan 2022 |
Grant Utility: Oxygen linked pyrimidine derivatives Filling date: 7 Nov 2019 Issue date: 5 Oct 2021 |
Application Filling date: 16 Nov 2020 Issue date: 11 Mar 2021 |
Application Filling date: 7 Nov 2019 Issue date: 5 Mar 2020 |
Grant Utility: Oxygen linked pyrimidine derivatives Filling date: 5 Jan 2017 Issue date: 31 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2022 6 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 7 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 8 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
VONJO Keeps CTI BioPharma A Buy
CTI BioPharma: Limited Cash Runway, But Better Than Expected Commercial Launch
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
CTI BioPharma: One Trick Pony Ready To Perform
CTI BioPharma: Approval Is Great, Now There's The Follow Through
CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
CTI BioPharma: A Speculative Buy Into The PDUFA Date
CTI BioPharma: Long And Troubled History, Finally Approaching Approval
-
When is CTI BioPharma Corp.'s next earnings date?
Unfortunately, CTI BioPharma Corp.'s (CTIC) next earnings date is currently unknown.
-
Does CTI BioPharma Corp. pay dividends?
No, CTI BioPharma Corp. does not pay dividends.
-
How much money does CTI BioPharma Corp. make?
CTI BioPharma Corp. has a market capitalization of 1.19B.
-
What is CTI BioPharma Corp.'s stock symbol?
CTI BioPharma Corp. is traded on the NASDAQ under the ticker symbol "CTIC".
-
What is CTI BioPharma Corp.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CTI BioPharma Corp.?
Shares of CTI BioPharma Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CTI BioPharma Corp.'s key executives?
CTI BioPharma Corp.'s management team includes the following people:
- Dr. Adam R. Craig Pres, Chief Executive Officer, Interim Chief Medical Officer & Director(age: 59, pay: $1,030,000)
- Mr. Bruce J. Seeley Executive Vice President & Chief Operating Officer(age: 61, pay: $598,000)
- Mr. David H. Kirske Executive Vice President, Chief Financial Officer & Sec.(age: 71, pay: $511,740)
-
How many employees does CTI BioPharma Corp. have?
As Jul 2024, CTI BioPharma Corp. employs 127 workers.
-
When CTI BioPharma Corp. went public?
CTI BioPharma Corp. is publicly traded company for more then 28 years since IPO on 21 Mar 1997.
-
What is CTI BioPharma Corp.'s official website?
The official website for CTI BioPharma Corp. is ctibiopharma.com.
-
Where are CTI BioPharma Corp.'s headquarters?
CTI BioPharma Corp. is headquartered at 3101 Western Avenue, Seattle, WA.
-
How can i contact CTI BioPharma Corp.?
CTI BioPharma Corp.'s mailing address is 3101 Western Avenue, Seattle, WA and company can be reached via phone at +20 62 827100.
CTI BioPharma Corp. company profile:
CTI BioPharma Corp.
ctibiopharma.comExchange:
NASDAQ
Full time employees:
127
Industry:
Biotechnology
Sector:
Healthcare
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
3101 Western Avenue
Seattle, WA 98121
Seattle, WA 98121
CIK: 0000891293
ISIN: US12648L6011
CUSIP: 12648L601
